# The Tolerability，Safety，PK/PD Study of rhTPO in the Patients With Liver Function Impairment

> **NCT03673215** · EARLY_PHASE1 · UNKNOWN · sponsor: **Shenyang Sunshine Pharmaceutical Co., LTD.** · enrollment: 58 (estimated)

## Conditions studied

- Liver Cirrhosis

## Interventions

- **DRUG:** Recombinant human thrombopoietin
- **DRUG:** Recombinant human thrombopoietin
- **DRUG:** Placebo
- **DRUG:** Recombinant human thrombopoietin
- **DRUG:** Placebo
- **DRUG:** recombinant human thrombopoietin
- **DRUG:** placebo
- **DRUG:** Recombinant human thrombopoietin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT03673215
- **Lead sponsor:** Shenyang Sunshine Pharmaceutical Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-28
- **Primary completion:** 2020-10-08
- **Final completion:** 2020-12-31
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2020-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03673215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03673215, "The Tolerability，Safety，PK/PD Study of rhTPO in the Patients With Liver Function Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03673215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*